Company Overview - Medline is the largest provider of medical-surgical products and supply chain solutions, offering 335,000 products and operating 33 manufacturing facilities in over 100 countries [2][3] - The company provides next-day delivery to 95% of its U.S. customers, positioning itself similarly to Amazon in the medical supply sector [2] Financial Performance - Medline has demonstrated impressive sales growth, with an average annual growth rate of 18% since its founding in 1966 and 50 consecutive years of net sales growth [8] - Sales are projected to reach around $30 billion for the full year 2026, up from $17.5 billion in 2020 [6][9] - Analysts expect earnings of $1.17 per share for 2025, with a nearly 20% increase to $1.52 per share in 2026 [9] Market Position and Competitive Advantage - Medline's competitive edge includes its private label products, which enhance margins by eliminating the need for third-party resellers [3] - The company is significantly more profitable than its key rivals, with a gross margin of approximately 27.4%, compared to much lower margins for competitors like McKesson and Cardinal Health [12] Growth Potential - The total addressable market for Medline is estimated at $375 billion, indicating substantial growth potential [9] - Free cash flow projections are robust, with expectations of $1.5 billion for 2025 and at least $2.1 billion for 2026, driven by debt reduction from IPO proceeds [10] Recent Developments - Medline recently went public with an IPO priced at $29 per share, raising $6.3 billion to pay down debt, which stood at $16.5 billion prior to the IPO [5][7] - The company was previously taken private in a $34 billion buyout in 2021, during which it expanded its manufacturing capabilities significantly [5][6] Investment Considerations - The company has a high P/E multiple of 28, and approximately 70% of its sales come from hospitals, which may present a concentration risk [13] - Private equity owners retain 60% of voting control, which could be a concern if fundamentals deteriorate, but their management has been effective [14]
How the Largest IPO of 2025 Could Be Healthy for Your Portfolio